^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Regimen: | (Herceptin (trastuzumab) + Perjeta (pertuzumab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
Excerpt:
...- Score 3+ by immunohistochemistry (IHC) or HER2 positive by Fluorescence in Situ Hybridization (FISH) method -...
Trial ID:
Source:
Title:
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Excerpt:
...Trastuzumab, for Her-2 positive disease 4....
Trial ID:
More C2 evidence
Source:
Title:
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
Excerpt:
...- Trastuzumab for Her-2 positive disease....
Trial ID:
Source:
Title:
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Excerpt:
...-- Patients must NOT have HER2 positive status based on ASCO/...
Trial ID:
Source:
Title:
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Excerpt:
...- HER2 positive as determined by score of 3 on immunohistochemistry (IHC) staining or gene amplification by fluorescence in situ hybridization (FISH)....
Trial ID:
Source:
Title:
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Excerpt:
...Trastuzumab is allowed in HER2 positive patients)....
Trial ID:
Source:
Title:
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
Excerpt:
...Previous treatment with a minimum of 4 cycles of neoadjuvant anthracycline and/or taxane containing chemotherapy (+trastuzumab in HER2-positive patients)....
Trial ID:
Source:
Title:
A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes
Excerpt:
...Patients with known HER2 positive tumors may additionally have been treated with trastuzumab and/or pertuzumab or trastuzumab emtasine in centers where this treatment is available....
Trial ID:
Less C2 evidence
Source:
Title:
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer
Published date:
07/24/2021
Excerpt:
We conducted a phase II study of eribulin mesylate, which extends survival in MBC, with HP in patients with previously treated HER2+ MBC to evaluate efficacy, toxicity, and genomic alterations driving therapeutic response. After a run-in phase for eribulin dosing, two cohorts were enrolled (Cohort A-no prior pertuzumab; Cohort B-prior pertuzumab). All patients received eribulin 1.4 mg/m2 on days 1, 8 with standard-dose HP on day 1 (21-day cycles). The six-patient run-in established a dose of eribulin 1.4 mg/m2 with HP. The ORR was 26.3% (95% Confidence Interval [CI] 9.2-51.2%) in Cohort A and 0% in Cohort B (95% CI 0-41.0%).
DOI:
10.1007/s10549-021-06329-x
Trial ID:
